1 / 1
Cagrilintide is a long-acting, chemically synthesized amylin receptor agonist, developed as a novel treatment for obesity and weight-related metabolic disorders. It is designed to mimic the effects of human amylin, a hormone co-secreted with insulin by pancreatic β-cells, which plays a crucial role in regulating food intake, gastric emptying, and satiety.
Cagrilintide is being developed as a once-weekly injectable therapy, offering a highly promising solution for chronic weight management, especially when used in combination with GLP-1 receptor agonists such as Semaglutide.
Cagrilintide exerts its therapeutic effects by binding to and activating amylin receptors, leading to:
Effectively targets neural signals to reduce central hunger cues.
Slowing digestion to significantly prolong the feeling of fullness.
Achieves reduced overall calorie intake through sustained mealtime satisfaction.
This multimodal regulation of food intake makes it an ideal candidate for managing obesity and related cardiometabolic risks.
Cagrilintide has shown promising results in several clinical trials, including Phase 2 studies conducted by Novo Nordisk:
This combination approach is a key part of the next-generation anti-obesity drug pipeline, targeting multiple satiety pathways (amylin + GLP-1).
Cagrilintide API Technical Specifications & Capabilities:
Cagrilintide represents a novel mechanism in weight management beyond GLP-1 monotherapy. Its complementary action profile makes it suitable for:
Cagrilintide is a long-acting, chemically synthesized amylin receptor agonist developed as an active pharmaceutical ingredient (API) targeting chronic obesity and weight-related metabolic disorders.
Unlike GLP-1 receptor agonists alone, Cagrilintide mimics human amylin to regulate food intake, delay gastric emptying, and enhance satiety. When combined with GLP-1 drugs like Semaglutide, it provides complementary pathways for superior weight loss.
In Phase 2 clinical trials, Cagrilintide monotherapy demonstrated up to 10.8% body weight reduction over 26 weeks, with even greater weight loss outcomes observed when combined with Semaglutide.
Cagrilintide API is manufactured using advanced Solid-Phase Peptide Synthesis (SPPS) technology to ensure high chemical purity, optimal stability, and suitability for injectable formulations.
The API is produced under strict quality control standards complying with global pharmaceutical requirements, including ICH, GMP, and FDA regulatory standards for clinical and commercial use.
